Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...
Fineline Cube
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...
China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure
The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...
NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...
Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...
Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China
The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...
NMPA Approves Expanded Production for COVID-19 Symptom Treatments
The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...
Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review
The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...
China Optimizes Medical Insurance Policies for COVID-19 Treatment
The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...
China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding
China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...
Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms
Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...
Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance
Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice...
Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study
China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...
China Strengthens COVID-19 Prevention and Control in Rural Areas
China has intensified its COVID-19 prevention and control measures in rural areas, with the State...
Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China
The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...
Changzhou Sifary Medtech Secures Series B Funding for Global Expansion
Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...
Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA
China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...